icon / home icon / small arrow right / light Team icon / small arrow right / light Univ. Prof. Dr. Nicole Meisner-Kober
Univ. Prof. Dr.

Nicole Meisner-Kober

Ludwig Boltzmann Institute for Nanovesicular Precision Medicine – Institute Director                                                     Paris Lodron University Salzburg – Professor of Chemical Biology and Biological Therapeutics                                              Department of Biosciences and Chemical Biology

Biomedical researcher dedicated to discovering and developing innovative therapies by combining chemistry with biology and unravelling basic pathophysiological mechanisms, with a focus on RNA and extracellular vesicle biology.

Nicole has a background in Molecular Biology and Biophysics and over 22 years of research and leadership experience both, in academia and the global pharmaceutical industry. Her team has made seminal contributions to the development of RNA delivery technologies and RNA drugs, as well as fundamental discoveries on the molecular mechanisms of posttranscriptional RNA regulation as well as RNA and EV trafficking biology.

She has a strong track record of developing partnerships and research structures for private-public partnerships and bridging between the academic, clinical and industry sectors, with 360° integration of stakeholders from relevant groups ranging from scientists, patients, clinicians, drug developers, funding bodies and policy makers to the public.

As an internationally established scientist in her field, she is engaged in several scientific advisory boards and has been regularly acting as member of scientific award juries, consultant for biotech and pharma companies as well as a scientific expert evaluator for private and public funding agencies, including the European Union.

Since 2018, Nicole has been actively engaged in forming close alliances between the Paris-Lodron University Salzburg (PLUS) with partners from the Paracelsus Medical University Salzburg (PMU) and the Salzburg University Hospital (SALK) to establish a new hub in Salzburg for discovery, development, manufacturing, and translation of Nanovesicular therapies from basic research into applications.